Tenaya Therapeutics Stock Discussion

$Tenaya Therapeutics (TNYA.US)$ Tenaya Therapeutics Shares Updates Related To Its Ongoing Phase 1b/2 MyPEAK-1 Clinical Trial Of TN-201; TN-201 Has Appropriate Tolerability Profile At 3E13 Vg/kg Dose Without Unexpected Adverse Reactions
Benzinga· 
TN-201 is being developed for the potential treatment of MYBPC3-associated hypertrophic cardiomyopathy (HCM), a condition caused by insufficient levels of myosin-binding protein C (MyBP-C).
TN-201 gene replacement the...

$Tenaya Therapeutics (TNYA.US)$
NEWS
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
Tenaya Therapeutics is demonstrating continuous innovation in core competencies at the ASGCT 27th Annual Meeting, showcasing its capabilities in genetic medicines for heart disease.
The company's pipeline includes two clinical-stage gene therapies for cardiomyopathies and research on ge...

$Tenaya Therapeutics (TNYA.US)$ The company’s lead product, TN-201, represents a significant advancement in treating genetic hypertrophic cardiomyopathy and is making headway in clinical trials. The anticipation of initial data from these trials in the second half of 2024 is seen as a pivotal moment that could substantially influence the company’s stock valuation.
Furthermore, Tenaya’s second gene therapy product, TN-401, is targeting the treatment of arrhythmogenic right...

$Tenaya Therapeutics (TNYA.US)$ Tenaya Therapeutics Publishes TN-401 Gene Therapy Preclinical Data In Nature Communications Medicine
Moomoo 24/7· 9 mins ago
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
PKP2 Gene Replacement Therapy Normalized Heart Rhythms, Reversed Disease Progression and Extended Survival in a Severe Mouse Model of Disease
Tenaya Anticipates Dosing First ...

$Tenaya Therapeutics (TNYA.US)$ might run today

$Tenaya Therapeutics (TNYA.US)$ Joseph Pantginis has given a Buy rating to Tenaya Therapeutics based on a number of factors. First and foremost, Pantginis highlights the FDA’s approval of Tenaya’s IND application for TN-401, an AAV9-based gene therapy aimed at treating arrhythmogenic right ventricular cardiomyopathy (ARVC). The clearance by the FDA to initiate clinical testing is seen as a significant step forward. Additionally, Tenaya’s plans to commence the RIDGE-1 Phase 1b trial, wh...

$Tenaya Therapeutics (TNYA.US)$ Tenaya Therapeutics Gets FDA Clearance To Begin Clinical Testing Of TN-401 Gene Therapy

$Tenaya Therapeutics (TNYA.US)$ Gap = Range > 2 Cent no good to trade better Delete out of Watchlist 👺😏👹